BRPI0812348B8 - método para regulação descedente ou de redução da função biológica de uma proteína,molécula quimérica,vetor recombinate e método para isolar uma proteína de uma amostra - Google Patents
método para regulação descedente ou de redução da função biológica de uma proteína,molécula quimérica,vetor recombinate e método para isolar uma proteína de uma amostraInfo
- Publication number
- BRPI0812348B8 BRPI0812348B8 BRPI0812348A BRPI0812348A BRPI0812348B8 BR PI0812348 B8 BRPI0812348 B8 BR PI0812348B8 BR PI0812348 A BRPI0812348 A BR PI0812348A BR PI0812348 A BRPI0812348 A BR PI0812348A BR PI0812348 B8 BRPI0812348 B8 BR PI0812348B8
- Authority
- BR
- Brazil
- Prior art keywords
- protein
- regulating
- isolating
- sample
- recombinant vector
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/30—Extraction; Separation; Purification by precipitation
- C07K1/32—Extraction; Separation; Purification by precipitation as complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
Abstract
método para regulação descendente ou de redução da função biológica de um proteína, molécula quimérica, vetor recombinante e método para isolar uma proteína de uma amostra. a presente invenção pertence à área técnica de agregação de proteínas. a invenção divulga um método para interferência na função de uma proteína alvo e utiliza uma molécula não natural, concebida por um usuário, designada como agregador, que possui uma especificidade para uma proteína alvo e que induz agregação ao contatar a referida proteína alvo. a presente invenção divulga igualmente essas moléculas agregadoras e o uso das mesmas em aplicações terapêuticas agregadoras e o uso das mesmas em aplicações terapêuticas e de diagnóstico.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93322707P | 2007-06-04 | 2007-06-04 | |
| US60/933.227 | 2007-06-04 | ||
| PCT/EP2008/056825 WO2008148751A1 (en) | 2007-06-04 | 2008-06-03 | Targeted induction of aggregation of proteins with cross beta structures |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0812348A2 BRPI0812348A2 (pt) | 2015-01-27 |
| BRPI0812348B1 BRPI0812348B1 (pt) | 2019-07-09 |
| BRPI0812348B8 true BRPI0812348B8 (pt) | 2021-05-25 |
Family
ID=39734210
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0812348A BRPI0812348B8 (pt) | 2007-06-04 | 2008-06-03 | método para regulação descedente ou de redução da função biológica de uma proteína,molécula quimérica,vetor recombinate e método para isolar uma proteína de uma amostra |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20100256069A1 (pt) |
| EP (1) | EP2162461B1 (pt) |
| JP (2) | JP5689680B2 (pt) |
| CN (2) | CN104758918A (pt) |
| AU (1) | AU2008258636B2 (pt) |
| BR (1) | BRPI0812348B8 (pt) |
| CA (1) | CA2689120C (pt) |
| DK (1) | DK2162461T3 (pt) |
| IL (1) | IL202355A (pt) |
| WO (1) | WO2008148751A1 (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8669418B2 (en) | 2005-12-22 | 2014-03-11 | Vib Vzw | Means and methods for mediating protein interference |
| EP2683419B1 (en) | 2011-03-11 | 2018-05-09 | Vib Vzw | Molecules and methods for inhibition and detection of proteins |
| US20150376637A1 (en) | 2013-01-29 | 2015-12-31 | The University Court Of The University Of Glasgow | Methods and means for increasing stress tolerance and biomass in plants |
| CA2917105C (en) | 2013-07-01 | 2023-09-26 | Bayer Cropscience Nv | Methods and means for modulating flowering time in monocot plants |
| WO2016050512A1 (en) | 2014-10-03 | 2016-04-07 | Bayer Cropscience Nv | Methods and means for increasing stress tolerance and biomass in plants |
| WO2018206732A1 (en) | 2017-05-09 | 2018-11-15 | Vib Vzw | Means and methods for treating bacterial infections |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6303567B1 (en) * | 1995-03-14 | 2001-10-16 | Praecis Pharmaceuticals, Inc . | Modulators of β-amyloid peptide aggregation comprising D-amino acids |
| US6743427B1 (en) * | 1997-12-02 | 2004-06-01 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| US20050026165A1 (en) * | 2001-05-31 | 2005-02-03 | Cindy Orser | Detection of conformationally altered proteins and prions |
| US7345022B2 (en) * | 2002-09-19 | 2008-03-18 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Anti-fibril peptides |
| WO2005118633A2 (en) * | 2004-05-20 | 2005-12-15 | The Whitehead Institute For Biomedical Research | Electrical conductors and devices from prion-like proteins |
| NZ554725A (en) * | 2004-10-25 | 2009-10-30 | Merck & Co Inc | Anti-ADDL antibodies and uses thereof |
| US8114832B2 (en) * | 2005-07-13 | 2012-02-14 | Crossbeta Biosciences B.V. | Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition |
| US20070015133A1 (en) * | 2005-07-13 | 2007-01-18 | Umc Utrecht Holding B.V. | Method for detecting and/or removing protein and/or peptide comprising a cross-beta structure from an aqueous solution comprising a protein |
| AU2006326940B2 (en) * | 2005-12-22 | 2012-04-19 | Vib Vzw | Means and methods for mediating protein interference |
-
2008
- 2008-06-03 CN CN201510053297.2A patent/CN104758918A/zh active Pending
- 2008-06-03 AU AU2008258636A patent/AU2008258636B2/en active Active
- 2008-06-03 JP JP2010510763A patent/JP5689680B2/ja active Active
- 2008-06-03 WO PCT/EP2008/056825 patent/WO2008148751A1/en active Application Filing
- 2008-06-03 EP EP08760409.6A patent/EP2162461B1/en active Active
- 2008-06-03 CN CN200880101841A patent/CN101772512A/zh active Pending
- 2008-06-03 CA CA2689120A patent/CA2689120C/en active Active
- 2008-06-03 BR BRPI0812348A patent/BRPI0812348B8/pt active IP Right Grant
- 2008-06-03 DK DK08760409.6T patent/DK2162461T3/en active
- 2008-06-03 US US12/602,910 patent/US20100256069A1/en not_active Abandoned
-
2009
- 2009-11-26 IL IL202355A patent/IL202355A/en active IP Right Grant
-
2014
- 2014-09-18 JP JP2014189675A patent/JP2015057387A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008258636B2 (en) | 2013-06-06 |
| CN101772512A (zh) | 2010-07-07 |
| DK2162461T3 (en) | 2017-07-10 |
| AU2008258636A1 (en) | 2008-12-11 |
| EP2162461B1 (en) | 2017-03-29 |
| BRPI0812348A2 (pt) | 2015-01-27 |
| WO2008148751A1 (en) | 2008-12-11 |
| JP5689680B2 (ja) | 2015-03-25 |
| EP2162461A1 (en) | 2010-03-17 |
| CN104758918A (zh) | 2015-07-08 |
| US20100256069A1 (en) | 2010-10-07 |
| CA2689120C (en) | 2017-07-11 |
| IL202355A (en) | 2015-11-30 |
| JP2015057387A (ja) | 2015-03-26 |
| CA2689120A1 (en) | 2008-12-11 |
| IL202355A0 (en) | 2010-06-30 |
| BRPI0812348B1 (pt) | 2019-07-09 |
| JP2010528637A (ja) | 2010-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012001984B8 (pt) | anticorpos humanos com alta afinidade para angiopoietina-2 humana, uso dos mesmos e composição farmacêutica | |
| BRPI0620125A8 (pt) | método para regulação de redução da função biológica de uma proteína, molécula de ocorrência não natural, vetor recombinante, e método para isolar uma protéina de uma amostra | |
| BR112018001374A2 (pt) | construtos de anticorpo biespecíficos que se ligam a egfrviii e cd3 | |
| BRPI0922350A2 (pt) | anticorpo humano, mólecula biespecífica,vetor de expressão, célula hospedeira eucariótica ou procariótoca recombinante, composição farmacêutica, uso do anticorpo ou da molécula biespecífica, métodos para inibir o desenvolvimento e/ou proliferação de uma célula tumoral que expressa o fator de tecido, para produzir um anticorpo, e para detectar a presença de fator de tecido em uma amostra, composição de diagnóstico, e, kit para detectar a presença de fator de tecido em uma amostra. | |
| AR092818A1 (es) | Anticuerpo tau humanizado | |
| BRPI0812348B8 (pt) | método para regulação descedente ou de redução da função biológica de uma proteína,molécula quimérica,vetor recombinate e método para isolar uma proteína de uma amostra | |
| BR112012019881A2 (pt) | proteínas de domínio estrutural baseadas na fibronectina que ligam-se à il-23 | |
| GB201020995D0 (en) | Biological materials and uses thereof | |
| ECSP14001249A (es) | Inmunoenlazadores dirigidos contra el tnf | |
| BR112014026740A8 (pt) | anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo | |
| BR112014031689A2 (pt) | anticorpos reativos cruzados anti-jagged 1/jagged 2, anticorpos anti-jagged ativáveis e métodos de uso deles | |
| BR112014008382A2 (pt) | anticorpo especificamente ligando a epítope no domínio sema do c-met | |
| BR112014023005A2 (pt) | diagnóstico rápido e tratamentos personalizados para acne | |
| UY35286A (es) | Construcciones de anticuerpos para CDH19 y CD3 | |
| BR112014028785A2 (pt) | proteínas de ligação a antígeno de st2 | |
| BR112015014751A2 (pt) | anticorpos anti-tau humanos | |
| BR112012008537A2 (pt) | processo de caracterização de pelo menos um micro-organismo por espectrometria de massa | |
| BR112016004324A2 (pt) | anticorpos | |
| BR112012004697A2 (pt) | purificação melhorada de proteína através de uma eluição da proteína a modificada. | |
| EA201401065A1 (ru) | Ang2-связывающие молекулы | |
| BR112015008347A2 (pt) | molécula de anticorpo isolada, uso de dita molécula de anticorpo, composição, ácido nucleico isolado, célula hospedeira, métodos para produção de uma molécula de anticorpo, para produzir um domínio de ligação de antígeno ao anticorpo para a?1-42 humano e para produzir um membro de ligação que se liga a a?1-42 humana. | |
| ATE553778T1 (de) | Für humanes hepcidin spezifische antikörper | |
| BR112016028534A2 (pt) | ceramidas e seu uso em diagnosticar cvd | |
| CL2009000862A1 (es) | Anticuerpo aislado, derivados o fragmentos aislados del mismo capaz de unirse a la proteina cd151, composición que lo comprende; ácido nucleico que lo codifica, vector y célula huesped que lo comprenden; procedimiento para preparar dicho anticuerpo; util como medicamento para prevenir o tratar el cáncer. | |
| BR112014031958A2 (pt) | bag3 como marcador de tecido e soro bioquímico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/07/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/07/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/06/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |